FAB
vs
207940
FAB
207940
Over the past 12 months, FAB has significantly outperformed Samsung Biologics Co Ltd, delivering a return of +70% compared to the Samsung Biologics Co Ltd's 0% growth.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
FAB
207940
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Fusion Antibodies PLC
LSE:FAB
|
14
GBX
|
|||||
|
Samsung Biologics Co Ltd
KRX:207940
|
999 999.9999
KRW
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
FAB, 207940
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
Fusion Antibodies PLC
Revenue
|
|||||||||||
|
Samsung Biologics Co Ltd
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
FAB, 207940
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
Fusion Antibodies PLC
LSE:FAB
|
|||||||||
|
Samsung Biologics Co Ltd
KRX:207940
|
|||||||||
Compare company's free cash flow with its competitors.
Gross Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Fusion Antibodies PLC | ||||
|
Samsung Biologics Co Ltd | ||||
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Fusion Antibodies PLC | ||||
|
Samsung Biologics Co Ltd | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Fusion Antibodies PLC | ||||
|
Samsung Biologics Co Ltd | ||||
FCF Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Fusion Antibodies PLC | ||||
|
Samsung Biologics Co Ltd | ||||
ROE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Fusion Antibodies PLC | ||||
|
Samsung Biologics Co Ltd | ||||
ROA
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Fusion Antibodies PLC | ||||
|
Samsung Biologics Co Ltd | ||||
ROIC
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Fusion Antibodies PLC | ||||
|
Samsung Biologics Co Ltd | ||||
ROCE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Fusion Antibodies PLC | ||||
|
Samsung Biologics Co Ltd | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
FAB, 207940
Performance By Year
FAB, 207940
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|